KINSY
Alhama de Murcia, Spain
Program data pending ClinicalTrials.gov matching
Profiled
Not yet scored
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
○ Press
○ EMA GMP
○ MHRA GMP
Quick Facts: KINSY
- Signal Score
- Profiled, not yet scored. Scores are published after regulatory evidence is attached and reviewed. How scoring works
- Headquarters
- Alhama de Murcia, Spain
- Website
- https://kinsy.es/en/
- Modalities
- Small Molecule API, Intermediates, Custom Synthesis
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
About KINSY
KINSY is a contract development and manufacturing organization (CDMO). Capabilities: Small Molecule API, Intermediates, Custom Synthesis. 1 manufacturing site registered with the U.S. FDA. Website: https://kinsy.es/en/
Signal Score
Profiled, not yet scored.
Scores are published after regulatory evidence is attached and reviewed.
How scoring works
Frequently Asked Questions About KINSY
Does KINSY have a CDMO Signal Score?
Not yet. KINSY is profiled, not yet scored. Scores are published after regulatory evidence is attached and reviewed.
Evaluating KINSY for a manufacturing program?
Use the free AI matchmaker to compare KINSY against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
Similar CDMOs
Menadiona
Palafolls, Barcelona, Spain
Intermediates, Small Molecule API, Custom Synthesis, Controlled Substances
Axplora
Paris, France
Small Molecule API, Intermediates, High-Potency APIs, Custom Synthesis
ICROM
Concorezzo (MB), Italy
Small Molecule API, Intermediates, Custom Synthesis
Divi's Laboratories
Hyderabad, Telangana, India
Small Molecule API, Intermediates, Custom Synthesis, Peptides
Lianhetech Seal Sands (Fine Organics Limited)
Middlesbrough, United Kingdom
Small Molecule API, Intermediates, Custom Synthesis
Compare KINSY with another CDMO
Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.